3D Human Cardiac Microtissues for Arrhythmia Risk Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cardiac toxicity testing methods, including in silico, in vitro, and animal models, are inadequate for predicting human cardiotoxicity, leading to high drug failure rates and unnecessary withdrawal of potentially safe compounds due to insufficient assessment of arrhythmia risks.
Innovation Solution
A three-dimensional human heart engineered tissue model (TEEM) that quantifies dose-dependent changes in electromechanical function, metabolic activity, and calcium signaling to predict cardiotoxicity, using human pluripotent stem cells to derive cardiomyocytes and cardiac fibroblasts, enabling screening for safe human exposure levels and personalized medicine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If in silico, in vitro, and animal models are used for cardiac toxicity testing, then screening coverage is achieved, but predictive accuracy for human cardiotoxicity is insufficient
Solution Approach 1:
The patent creates a human-specific in vitro model using induced pluripotent stem cell-derived cardiomyocytes that replicate human cardiac electrophysiology and calcium handling. This copying approach replaces non-human models with human cell-based systems, directly improving predictive accuracy for human cardiotoxicity while maintaining screening capability
Solution Approach 2:
The patent measures multiple electrophysiological parameters including action potential duration, calcium transient amplitude, and beat rate. By monitoring changes in these parameters in response to drug exposure, the system achieves precise arrhythmia risk assessment that overcomes the limitations of traditional single-parameter models
2Measurement precision
If traditional in vitro models are used, then screening throughput is maintained, but differentiation between high-risk and low-risk compounds is insufficient
Solution Approach 1:
The patent develops a multi-functional assay platform that simultaneously measures electrophysiological parameters, calcium signaling, and cellular morphology. This universal system can evaluate multiple aspects of cardiotoxicity in a single experiment, enabling precise compound differentiation without sacrificing screening throughput
Solution Approach 2:
The patent replaces mechanical/electrical recording systems with optical detection methods using voltage-sensitive and calcium-sensitive dyes. This substitution enables high-throughput imaging and automated analysis, maintaining productivity while achieving superior compound risk differentiation through multiple optical parameters
3Reliability
If comprehensive cardiac safety evaluation is performed, then patient safety is improved, but drug development costs and time increase
Solution Approach 1:
The patent performs comprehensive cardiac safety evaluation using human-specific in vitro models during early drug development stages. By conducting thorough electrophysiological and calcium signaling assessments before clinical trials, the system identifies cardiotoxic compounds early, preventing later failures and reducing overall development time despite intensive initial testing
Data Source
AI summary
The Cardiac Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.